Compare Nebius Group NV (NBIS) vs Revvity Inc (RVTY) Price & Performance

NBIS trades at $221.12, down 6.73% over 24 hours amid a bearish technical signal. The stock shows strong analyst support with an 81.82% buy rating and a $288.67 consensus price target, but faces high valuations with a P/E of 845.04 and negative earnings in recent quarters. Recent news highlights AI infrastructure growth potential, including a $37 billion backlog and strategic acquisitions like Inferize, though insider selling and competitive pressures pose concerns.

The outlook for NBIS hinges on executing its AI cloud expansion, with revenue projected to surge from $530 million in 2025 to $1.4 billion in 2026. Risks include elevated debt from aggressive investing, negative net income margins, and potential AI market volatility. The stock offers upside if growth targets are met but remains sensitive to sector sentiment and financing stability.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.